Published in EMBO J on May 26, 2005
Towards an HIV cure: a global scientific strategy. Nat Rev Immunol (2012) 5.52
Plasma membrane is the site of productive HIV-1 particle assembly. PLoS Biol (2006) 4.43
Dendritic-cell interactions with HIV: infection and viral dissemination. Nat Rev Immunol (2006) 3.80
Setting the stage: host invasion by HIV. Nat Rev Immunol (2008) 3.25
Cellular microRNA expression correlates with susceptibility of monocytes/macrophages to HIV-1 infection. Blood (2008) 2.96
In macrophages, HIV-1 assembles into an intracellular plasma membrane domain containing the tetraspanins CD81, CD9, and CD53. J Cell Biol (2007) 2.68
Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs. Nat Rev Microbiol (2009) 2.47
HIV-1 buds predominantly at the plasma membrane of primary human macrophages. PLoS Pathog (2007) 2.44
Real-time visualization of HIV-1 GAG trafficking in infected macrophages. PLoS Pathog (2008) 2.32
High multiplicity HIV-1 cell-to-cell transmission from macrophages to CD4+ T cells limits antiretroviral efficacy. AIDS (2013) 2.25
Macrophages in vaginal but not intestinal mucosa are monocyte-like and permissive to human immunodeficiency virus type 1 infection. J Virol (2009) 1.84
Ion-abrasion scanning electron microscopy reveals surface-connected tubular conduits in HIV-infected macrophages. PLoS Pathog (2009) 1.70
Productive human immunodeficiency virus type 1 assembly takes place at the plasma membrane. J Virol (2007) 1.66
Restriction of HIV-1 replication in macrophages and CD4+ T cells from HIV controllers. Blood (2011) 1.62
Latency: the hidden HIV-1 challenge. Retrovirology (2006) 1.59
Gag- and Nef-specific CD4+ T cells recognize and inhibit SIV replication in infected macrophages early after infection. Proc Natl Acad Sci U S A (2009) 1.51
Vpu and Tsg101 regulate intracellular targeting of the human immunodeficiency virus type 1 core protein precursor Pr55gag. J Virol (2006) 1.50
Macrophages and their relevance in Human Immunodeficiency Virus Type I infection. Retrovirology (2012) 1.41
Curing HIV: Pharmacologic approaches to target HIV-1 latency. Annu Rev Pharmacol Toxicol (2011) 1.38
HIV-1 persists in breast milk cells despite antiretroviral treatment to prevent mother-to-child transmission. AIDS (2008) 1.36
Host hindrance to HIV-1 replication in monocytes and macrophages. Retrovirology (2010) 1.33
p21-mediated RNR2 repression restricts HIV-1 replication in macrophages by inhibiting dNTP biosynthesis pathway. Proc Natl Acad Sci U S A (2013) 1.31
HIV reservoirs and latency models. Virology (2011) 1.29
Vpu serine 52 dependent counteraction of tetherin is required for HIV-1 replication in macrophages, but not in ex vivo human lymphoid tissue. Retrovirology (2010) 1.28
HIV-1 assembly in macrophages. Retrovirology (2010) 1.20
Macrophage internal HIV-1 is protected from neutralizing antibodies. J Virol (2011) 1.19
High-multiplicity HIV-1 infection and neutralizing antibody evasion mediated by the macrophage-T cell virological synapse. J Virol (2013) 1.15
HIV-1 latency in monocytes/macrophages. Viruses (2014) 1.13
HIV-1 Assembly at the Plasma Membrane: Gag Trafficking and Localization. Future Virol (2009) 1.11
Innate and adaptive anti-HIV immune responses in the female reproductive tract. J Reprod Immunol (2013) 1.09
miRNA profiles of monocyte-lineage cells are consistent with complicated roles in HIV-1 restriction. Viruses (2012) 1.09
HIV latency: present knowledge, future directions. Future Virol (2006) 1.04
Human immunodeficiency virus type 1 endocytic trafficking through macrophage bridging conduits facilitates spread of infection. J Neuroimmune Pharmacol (2011) 1.02
Macrophages and HIV-1: An Unhealthy Constellation. Cell Host Microbe (2016) 1.02
Endosomal trafficking of HIV-1 gag and genomic RNAs regulates viral egress. J Biol Chem (2009) 1.01
The engagement of activating FcgammaRs inhibits primate lentivirus replication in human macrophages. J Immunol (2006) 1.00
Major histocompatibility complex class II molecules promote human immunodeficiency virus type 1 assembly and budding to late endosomal/multivesicular body compartments. J Virol (2006) 0.98
IL-27 inhibits HIV-1 infection in human macrophages by down-regulating host factor SPTBN1 during monocyte to macrophage differentiation. J Exp Med (2013) 0.98
Macrophage bridging conduit trafficking of HIV-1 through the endoplasmic reticulum and Golgi network. J Proteome Res (2011) 0.97
Critical role for the kinesin KIF3A in the HIV life cycle in primary human macrophages. J Cell Biol (2012) 0.97
The majority of freshly sorted simian immunodeficiency virus (SIV)-specific CD8(+) T cells cannot suppress viral replication in SIV-infected macrophages. J Virol (2012) 0.97
Human immunodeficiency virus (HIV) latency: the major hurdle in HIV eradication. Mol Med (2012) 0.96
Antiviral efficacy of the novel compound BIT225 against HIV-1 release from human macrophages. Antimicrob Agents Chemother (2009) 0.96
Genetically modified hematopoietic stem cell transplantation for HIV-1-infected patients: can we achieve a cure? Mol Ther (2013) 0.95
Interferon block to HIV-1 transduction in macrophages despite SAMHD1 degradation and high deoxynucleoside triphosphates supply. Retrovirology (2013) 0.94
Heme oxygenase-1 induction alters chemokine regulation and ameliorates human immunodeficiency virus-type-1 infection in lipopolysaccharide-stimulated macrophages. Biochem Biophys Res Commun (2013) 0.93
HIV-1 Trans Infection of CD4(+) T Cells by Professional Antigen Presenting Cells. Scientifica (Cairo) (2013) 0.93
Three-dimensional imaging of HIV-1 virological synapses reveals membrane architectures involved in virus transmission. J Virol (2014) 0.92
Stromal down-regulation of macrophage CD4/CCR5 expression and NF-κB activation mediates HIV-1 non-permissiveness in intestinal macrophages. PLoS Pathog (2011) 0.92
Herpes simplex virus-induced epithelial damage and susceptibility to human immunodeficiency virus type 1 infection in human cervical organ culture. PLoS One (2011) 0.92
CD36-specific antibodies block release of HIV-1 from infected primary macrophages and its transmission to T cells. J Exp Med (2013) 0.90
HIV-1 interactions with cells: from viral binding to cell-cell transmission. Curr Protoc Cell Biol (2009) 0.90
Organization and regulation of intracellular plasma membrane-connected HIV-1 assembly compartments in macrophages. BMC Biol (2013) 0.89
Quantitative GPCR and ion channel transcriptomics in primary alveolar macrophages and macrophage surrogates. BMC Immunol (2012) 0.88
Nef Is Dispensable for Resistance of Simian Immunodeficiency Virus-Infected Macrophages to CD8+ T Cell Killing. J Virol (2015) 0.87
Feline lectin activity is critical for the cellular entry of feline infectious peritonitis virus. J Virol (2010) 0.86
Cellular microvesicle pathways can be targeted to transfer genetic information between non-immune cells. PLoS One (2009) 0.86
Dynamic Association between HIV-1 Gag and Membrane Domains. Mol Biol Int (2012) 0.84
Immunobiology of genital tract trauma: endocrine regulation of HIV acquisition in women following sexual assault or genital tract mutilation. Am J Reprod Immunol (2012) 0.84
Intravital microscopy in BLT-humanized mice to study cellular dynamics in HIV infection. J Infect Dis (2013) 0.83
Molecular mechanisms of HIV immune evasion of the innate immune response in myeloid cells. Viruses (2012) 0.82
Catching HIV 'in the act' with 3D electron microscopy. Trends Microbiol (2013) 0.82
Role of the long cytoplasmic domain of the SIV Env glycoprotein in early and late stages of infection. Retrovirology (2007) 0.81
Mucosal immunity in the female genital tract, HIV/AIDS. Biomed Res Int (2014) 0.81
Role of Gag and lipids during HIV-1 assembly in CD4(+) T cells and macrophages. Front Microbiol (2014) 0.81
Pattern Recognition Receptors in HIV Transmission. Front Immunol (2012) 0.80
The Envelope Cytoplasmic Tail of HIV-1 Subtype C Contributes to Poor Replication Capacity through Low Viral Infectivity and Cell-to-Cell Transmission. PLoS One (2016) 0.80
The antiviral compound BIT225 inhibits HIV-1 replication in myeloid dendritic cells. AIDS Res Ther (2016) 0.80
Genetic similarity of circulating and small intestinal virus at the end stage of acute pathogenic simian-human immunodeficiency virus infection. Front Microbiol (2013) 0.79
Caveolin-1 reduces HIV-1 infectivity by restoration of HIV Nef mediated impairment of cholesterol efflux by apoA-I. Retrovirology (2012) 0.79
HIV Maintains an Evolving and Dispersed Population in Multiple Tissues during Suppressive Combined Antiretroviral Therapy in Individuals with Cancer. J Virol (2016) 0.78
Placental Hofbauer cells assemble and sequester HIV-1 in tetraspanin-positive compartments that are accessible to broadly neutralizing antibodies. J Int AIDS Soc (2015) 0.78
Inhibition of HIV Expression and Integration in Macrophages by Methylglyoxal-Bis-Guanylhydrazone. J Virol (2015) 0.78
The number and genetic relatedness of transmitted/founder virus impact clinical outcome in vaginal R5 SHIVSF162P3N infection. Retrovirology (2014) 0.78
The intracellular plasma membrane-connected compartment in the assembly of HIV-1 in human macrophages. BMC Biol (2016) 0.78
Extracellular ATP induces the rapid release of HIV-1 from virus containing compartments of human macrophages. Proc Natl Acad Sci U S A (2015) 0.78
Effects of Succinic Acid and Other Microbial Fermentation Products on HIV Expression in Macrophages. Biores Open Access (2013) 0.77
3D correlative light and electron microscopy of cultured cells using serial blockface scanning electron microscopy. J Cell Sci (2016) 0.76
CD4-independent use of the CCR5 receptor by sequential primary SIVsm isolates. Retrovirology (2007) 0.76
Molecular Determinants Directing HIV-1 Gag Assembly to Virus-Containing Compartments in Primary Macrophages. J Virol (2016) 0.75
Colony-Stimulating Factor 1 Receptor Antagonists Sensitize Human Immunodeficiency Virus Type 1-Infected Macrophages to TRAIL-Mediated Killing. J Virol (2016) 0.75
Sulforaphane Inhibits HIV Infection of Macrophages through Nrf2. PLoS Pathog (2016) 0.75
Occludin controls HIV transcription in brain pericytes via regulation of SIRT-1 activation. FASEB J (2015) 0.75
Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science (1997) 18.10
Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature (1997) 15.49
Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science (1997) 15.12
DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell (2000) 14.43
Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A (1997) 13.47
Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J Virol (1992) 12.89
Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med (1999) 12.68
Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes. J Exp Med (1988) 9.21
The biogenesis of multivesicular endosomes. Nat Rev Mol Cell Biol (2004) 6.31
Modulation of HIV-1 replication by RNA interference. Nature (2002) 5.90
Dendritic cells exposed to human immunodeficiency virus type-1 transmit a vigorous cytopathic infection to CD4+ T cells. Science (1992) 5.61
Infectious HIV-1 assembles in late endosomes in primary macrophages. J Cell Biol (2003) 4.68
DC-SIGN-mediated internalization of HIV is required for trans-enhancement of T cell infection. Immunity (2002) 4.62
Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy. Nat Med (2000) 4.12
Human macrophages accumulate HIV-1 particles in MHC II compartments. Traffic (2002) 3.39
Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. J Infect Dis (2004) 3.30
Cell-type-dependent targeting of human immunodeficiency virus type 1 assembly to the plasma membrane and the multivesicular body. J Virol (2004) 3.22
HIV-1 Nef intersects the macrophage CD40L signalling pathway to promote resting-cell infection. Nature (2003) 2.90
HIV-1 pathogenesis. Nat Med (2003) 2.88
DC-SIGNR, a DC-SIGN homologue expressed in endothelial cells, binds to human and simian immunodeficiency viruses and activates infection in trans. Proc Natl Acad Sci U S A (2001) 2.86
Human immunodeficiency virus type 1 Gag proteins are processed in two cellular compartments. Proc Natl Acad Sci U S A (1991) 2.80
Rapid and efficient cell-to-cell transmission of human immunodeficiency virus infection from monocyte-derived macrophages to peripheral blood lymphocytes. Virology (1999) 2.27
Interactions between HIV1 Nef and vacuolar ATPase facilitate the internalization of CD4. Immunity (1998) 2.08
DC-SIGN promotes exogenous MHC-I-restricted HIV-1 antigen presentation. Blood (2003) 1.89
Strict control of human immunodeficiency virus type 1 replication by a genetic switch: Tet for Tat. J Virol (2001) 1.89
Characterization of restrictions to human immunodeficiency virus type 1 infection of monocytes. J Virol (2004) 1.52
The role of endosomes and lysosomes in MHC class II functioning. Immunol Today (1998) 1.51
Human immunodeficiency virus type 1 Gag contains a dileucine-like motif that regulates association with multivesicular bodies. J Virol (2004) 1.32
The HIV-1 Vpu protein: a multifunctional enhancer of viral particle release. Microbes Infect (2003) 1.24
Human immunodeficiency virus-1 Nef expression induces intracellular accumulation of multivesicular bodies and major histocompatibility complex class II complexes: potential role of phosphatidylinositol 3-kinase. Mol Biol Cell (2003) 1.18
Nef proteins encoded by human and simian immunodeficiency viruses induce the accumulation of endosomes and lysosomes in human T cells. Proc Natl Acad Sci U S A (1997) 1.13
In vitro inhibition of human immunodeficiency virus (HIV) type 1 replication by C2 symmetry-based HIV protease inhibitors as single agents or in combinations. Antimicrob Agents Chemother (1992) 1.13
Viral protein U (Vpu)-mediated enhancement of human immunodeficiency virus type 1 particle release depends on the rate of cellular proliferation. J Virol (2001) 0.93
Negative factor from SIV binds to the catalytic subunit of the V-ATPase to internalize CD4 and to increase viral infectivity. Mol Biol Cell (2001) 0.92
Quantitative competitive RNA PCR for quantitation of virion-associated HIV-1 RNA. Methods (1997) 0.82
The positive influence of Nef on viral infectivity. Res Virol (1997) 0.81
[Different sensitivity to acid reaction of the AIDS virus and virus-producing cells: clinical conclusions]. Orv Hetil (1990) 0.79
Modulation of HIV-1 replication by RNA interference. Nature (2002) 5.90
Towards an HIV cure: a global scientific strategy. Nat Rev Immunol (2012) 5.52
HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med (2010) 5.36
Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Science (2004) 5.31
Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc Natl Acad Sci U S A (2014) 2.95
HIV-1 Nef intersects the macrophage CD40L signalling pathway to promote resting-cell infection. Nature (2003) 2.90
Small-molecule inhibition of HIV-1 Vif. Nat Biotechnol (2008) 2.83
Primate lentiviral Vpx commandeers DDB1 to counteract a macrophage restriction. PLoS Pathog (2008) 2.72
A cellular restriction dictates the permissivity of nondividing monocytes/macrophages to lentivirus and gammaretrovirus infection. Cell Host Microbe (2009) 2.34
The inner-nuclear-envelope protein emerin regulates HIV-1 infectivity. Nature (2006) 2.02
In vivo evidence for instability of episomal human immunodeficiency virus type 1 cDNA. J Virol (2005) 1.80
Apoptotic killing of HIV-1-infected macrophages is subverted by the viral envelope glycoprotein. PLoS Pathog (2007) 1.61
Characterization of restrictions to human immunodeficiency virus type 1 infection of monocytes. J Virol (2004) 1.52
Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study. Antivir Ther (2011) 1.41
Episomal viral cDNAs identify a reservoir that fuels viral rebound after treatment interruption and that contributes to treatment failure. PLoS Pathog (2011) 1.32
Evidence for a pathogenic determinant in HIV-1 Nef involved in B cell dysfunction in HIV/AIDS. Cell Host Microbe (2008) 1.31
Evidence for a cytopathogenicity determinant in HIV-1 Vpr. Proc Natl Acad Sci U S A (2002) 1.27
Inhibition of human immunodeficiency virus type 1 replication by RNA interference directed against human transcription elongation factor P-TEFb (CDK9/CyclinT1). J Virol (2004) 1.26
Progress toward a human CD4/CCR5 transgenic rat model for de novo infection by human immunodeficiency virus type 1. J Exp Med (2002) 1.23
Deep molecular characterization of HIV-1 dynamics under suppressive HAART. PLoS Pathog (2011) 1.21
Advances in macrophage and dendritic cell biology in HIV-1 infection stress key understudied areas in infection, pathogenesis, and analysis of viral reservoirs. J Leukoc Biol (2006) 1.19
In-depth analysis of the interaction of HIV-1 with cellular microRNA biogenesis and effector mechanisms. MBio (2013) 1.18
Overcoming pharmacologic sanctuaries. Curr Opin HIV AIDS (2013) 1.17
Modest but reproducible inhibition of human immunodeficiency virus type 1 infection in macrophages following LEDGFp75 silencing. J Virol (2006) 1.14
HIV and cells of macrophage/dendritic lineage and other non-T cell reservoirs: new answers yield new questions. J Leukoc Biol (2003) 1.13
Importin 7 may be dispensable for human immunodeficiency virus type 1 and simian immunodeficiency virus infection of primary macrophages. J Virol (2005) 1.06
Modulating HIV-1 replication by RNA interference directed against human transcription elongation factor SPT5. Retrovirology (2004) 1.05
Mutation detection using ENDO1: application to disease diagnostics in humans and TILLING and Eco-TILLING in plants. BMC Mol Biol (2008) 1.01
The search for a cure for persistent HIV reservoirs. AIDS Rev (2011) 0.98
The majority of freshly sorted simian immunodeficiency virus (SIV)-specific CD8(+) T cells cannot suppress viral replication in SIV-infected macrophages. J Virol (2012) 0.97
Identification of flavopiridol analogues that selectively inhibit positive transcription elongation factor (P-TEFb) and block HIV-1 replication. Chembiochem (2009) 0.95
HIV type 1 infection up-regulates TLR2 and TLR4 expression and function in vivo and in vitro. AIDS Res Hum Retroviruses (2012) 0.89
HIV-1 replication increases HIV-specific CD4+ T cell frequencies but limits proliferative capacity in chronically infected children. J Immunol (2003) 0.89
A highly conserved residue in the C-terminal helix of HIV-1 matrix is required for envelope incorporation into virus particles. J Virol (2011) 0.89
Synthesis and structure-activity relationship studies of HIV-1 virion infectivity factor (Vif) inhibitors that block viral replication. ChemMedChem (2012) 0.87
Dynamics of CD8 T-cell activation after discontinuation of HIV treatment intensification. J Acquir Immune Defic Syndr (2013) 0.86
Env-expressing autologous T lymphocytes induce neutralizing antibody and afford marked protection against feline immunodeficiency virus. J Virol (2010) 0.81
A novel motif in HIV-1 Nef that regulates MIP-1beta chemokine release in macrophages. J Virol (2010) 0.80
Glucocorticoid treatment at moderate doses of SIVmac251-infected rhesus macaques decreases the frequency of circulating CD14+CD16++ monocytes but does not alter the tissue virus reservoir. AIDS Res Hum Retroviruses (2015) 0.77
TRIMming HIV-1's mainsail. Nat Immunol (2004) 0.76
Tat's seductive side. Nat Med (2003) 0.75
Highlights from the 2012 International Symposium on HIV & Emerging Infectious Diseases (ISHEID): from cART management to the search of an HIV cure. AIDS Res Ther (2012) 0.75
Zika Virus: Obstetric and Pediatric Anesthesia Considerations. Anesth Analg (2017) 0.75
Unsung hero Robert C. Gallo. Science (2009) 0.75
A plea for justice for jailed medical workers. Science (2006) 0.75